Pharvaris (NASDAQ:PHVS) Director Sells $115,168.10 in Stock

Pharvaris N.V. (NASDAQ:PHVS) Director Johannes Gerardus Chri Schikan sold 3,830 shares of the business’s stock in a transaction on Wednesday, April 29th. The shares were sold at an average price of $30.07, for a total transaction of $115,168.10. Following the transaction, the director directly owned 384,237 shares of the company’s stock, valued at approximately $11,554,006.59. This trade represents a 0.99% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

Johannes Gerardus Chri Schikan also recently made the following trade(s):

• On Thursday, April 30th, Johannes Gerardus Chri Schikan sold 29,070 shares of Pharvaris stock. The shares were sold at an average price of $30.32, for a total transaction of $881,402.40.
• On Thursday, April 23rd, Johannes Gerardus Chri Schikan sold 100 shares of Pharvaris stock. The shares were sold at an average price of $30.03, for a total transaction of $3,003.00.
• On Wednesday, April 22nd, Johannes Gerardus Chri Schikan sold 7,000 shares of Pharvaris stock. The shares were sold at an average price of $30.05, for a total transaction of $210,350.00.

Pharvaris Stock Performance

Shares of PHVS traded down $1.57 during midday trading on Friday, hitting $29.44. 512,191 shares of the stock traded hands, compared to its average volume of 245,049. Pharvaris N.V. has a 1-year low of $14.59 and a 1-year high of $31.14. The business’s 50 day moving average price is $27.62 and its two-hundred day moving average price is $26.03.

Pharvaris (NASDAQ:PHVS) last announced its quarterly earnings results on Friday, April 3rd. The company reported ($0.84) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.69) by ($0.15). As a group, equities analysts anticipate that Pharvaris N.V. will post -3.19 earnings per share for the current year.

Institutional Investors Weigh In On Pharvaris

A number of hedge funds and other institutional investors have recently modified their holdings of PHVS. General Atlantic L.P. raised its position in Pharvaris by 6.6% in the third quarter. General Atlantic L.P. now owns 8,031,252 shares of the company’s stock worth $200,380,000 after acquiring an additional 500,000 shares in the last quarter. Foresite Capital Management IV LLC lifted its holdings in Pharvaris by 8.3% in the 3rd quarter. Foresite Capital Management IV LLC now owns 4,778,581 shares of the company’s stock valued at $119,226,000 after acquiring an additional 368,000 shares during the last quarter. venBio Partners LLC lifted its holdings in Pharvaris by 8.2% in the 3rd quarter. venBio Partners LLC now owns 4,639,304 shares of the company’s stock valued at $115,751,000 after acquiring an additional 350,000 shares during the last quarter. Deerfield Management Company L.P. lifted its holdings in Pharvaris by 21.1% in the 3rd quarter. Deerfield Management Company L.P. now owns 2,442,464 shares of the company’s stock valued at $60,939,000 after acquiring an additional 425,000 shares during the last quarter. Finally, Commodore Capital LP lifted its holdings in Pharvaris by 26.5% in the 3rd quarter. Commodore Capital LP now owns 2,418,476 shares of the company’s stock valued at $60,341,000 after acquiring an additional 507,043 shares during the last quarter.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on PHVS. Wedbush boosted their price target on shares of Pharvaris from $41.00 to $42.00 and gave the company an “outperform” rating in a report on Tuesday, April 7th. HC Wainwright restated a “buy” rating and set a $60.00 price objective on shares of Pharvaris in a research note on Tuesday, March 3rd. Wall Street Zen cut shares of Pharvaris from a “sell” rating to a “strong sell” rating in a research note on Monday, April 13th. Royal Bank Of Canada cut their price objective on shares of Pharvaris from $52.00 to $51.00 and set an “outperform” rating on the stock in a research note on Monday, April 6th. Finally, Wolfe Research began coverage on shares of Pharvaris in a research note on Thursday, April 9th. They set an “outperform” rating and a $42.00 price objective on the stock. Eleven equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Pharvaris currently has a consensus rating of “Moderate Buy” and an average target price of $42.73.

Pharvaris Company Profile

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.